9 completed. 2 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow iberogast: new trials by email Literature Review of iberogast trials Research Report on iberogast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting Iberogast (STW5-II, BAY98-7410) - Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome | Completed | Bayer | 184 | 2022-06-04 | 2023-12-26 | |
| Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Iberogast® and Iberogast® N - Irritable Bowel Syndrome, Functional Dyspepsia | Phase 4 | Completed | Hospital Vall d'Hebron | 68 | 2020-09-03 | 2023-09-22 |
| A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome Iberogast (STW5, BAY98-7411) - Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia | Completed | Bayer | 843 | 2017-11-16 | 2021-08-06 | |
| Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease IBEROGAST - Gastrointestinal Disorders in Parkinson's Disease | Phase 2 | Completed | Nantes University Hospital | 45 | 2016-04-01 | 2026-09-14 |
| Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea Acupressure, Placebo-band, Iberogast - Functional Nausea | Not applicable | Completed | University Hospital, Basel, Switzerland | 56 | 2016-01-01 | 2020-10-06 |
| Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo STW5 (Iberogast, BAY98-7411), Placebo - Irritable Bowel Syndrome | Phase 3 | Completed | Bayer | 243 | 2013-10-11 | 2018-10-29 |
| Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus STW5 (Iberogast®, BAY98-7411), Placebo - Functional Gastrointestinal Disorders | Phase 2 | Completed | Bayer | 64 | 2009-06-18 | 2019-09-19 |
| Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function STW5 (Iberogast®, BAY98-7411) - Functional Gastrointestinal Disorders | Completed | Bayer | 272 | 2008-06-17 | 2019-09-19 | |
| Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years Iberogast® - Functional Gastrointestinal Disorders | Completed | Bayer | 1032 | 2007-04-01 | 2019-09-19 |
Irritable Bowel Syndrome (4) · Gastrointestinal Diseases (3) · Digestive System Diseases (1)
Bayer (6) · Hospital Vall d'Hebron (1) · Nantes University Hospital (1) · University Hospital, Basel, Switzerland (1)
Germany (6) · France (1) · Spain (1) · Switzerland (1)
2008 (1)